Pricing Log in Create free account
Saturday 17 October 2026 Export CRL’s income statement to Excel — free account

Charles River Laboratories International, Inc.

CRL Healthcare Diagnostics & Research

Charles River Laboratories International, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 billion, down 0.85% from fiscal 2024. In the quarter to June 2026, revenue fell 2.72%, EPS fell 102.8%, free cash flow fell 12.2% and total debt rose 12.3%, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

299.77 6.47 −2.11%
Market cap
$14.6B
P/E
0.0×
Fwd P/E
29.6×
Dividend yield
—
F-score
5/9
Altman Z
2.40
Beneish M
−3.11
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Charles River Laboratories International, Inc. (CRL) Price to free cash flow

Alert me on Price to free cash flow

As of 16 October 2026, Charles River Laboratories International, Inc. (CRL) trades at a price to free cash flow of 38.8×. Over the past ten years it has ranged from 9.0× (April 2025) to 50.0× (October 2021); the current reading is higher than 93% of that period. That is above the Diagnostics & Research industry median of 35.8× and above the Healthcare sector median of 20.2×.

Price to free cash flow, daily

Embed this chart

Annual newest first

Period Price to free cash flow Change
FY2025 19.1× 0.85%
FY2024 18.9× (42.43%)
FY2023 32.8× (12.72%)
FY2022 37.6× 5.65%
FY2021 35.6× 9.33%
FY2020 32.6× 48.99%
FY2019 21.9× 21.32%
FY2018 18.0× (19.16%)
FY2017 22.3× 62.11%
FY2016 13.8× (10.38%)

Quarterly newest first

Period Price to free cash flow Change
Jun 2026 29.4× 36.17%
Mar 2026 21.6× 13.17%
Dec 2025 19.1× 34.64%
Sep 2025 14.2× 9.87%
42 more quarters

Against its own ten years

Low 9.0× High 50.0×
Ten-year median 22.1×
Current reading's percentile 93

Price to free cash flow against peers

Company Price to free cash flow
TWST Twist Bioscience Corporation compare n/m
GH Guardant Health, Inc. compare n/m
ICLR ICON PLC compare 14.8×
DGX Quest Diagnostics Incorporated compare 19.3×
QGEN QIAGEN N.V. compare 21.6×
MEDP Medpace Holdings, Inc. compare 24.7×
LH Labcorp Holdings Inc. compare 25.2×
RVTY Revvity Inc. compare 30.1×
CRL Charles River Laboratories International, Inc. 38.8×
Diagnostics & Research industry median 35.8×
Healthcare sector median 20.2×
Market median 14.2×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

More on CRL